Table 1.

Characteristics of 156 patients with CLL analyzed in longitudinal genomic analysis

Patient characteristicsNo intercurrent therapy no. (%)Intercurrent therapy no. (%)
Sample size N = 156 patients114 (73%)42 (27%)
Age at enrollment, y
 Median6263
 Range40–9039–84
Gender
 Female43 (38%)12 (29%)
 Male71 (62%)30 (71%)
Rai stage at enrollment
 Low, 064 (56%)8 (19%)
 Intermediate, I–II50 (44%)29 (69%)
 High, III–IV0 (0%)5 (12%)
NOTCH1 Exon 34 mutations at enrollment
 Wild-type106 (93%)35 (83%)
 Mutated8 (7%)7 (17%)
SF3B1 Exons 13–17 mutations at enrollment
 Wild-type111 (97%)36 (86%)
 Mutated2 (2%)6 (14%)
SF3B1 Data not available1 (1%)0 (0%)
P53 exons 2–10 mutations at enrollment
 Wild-type104 (91%)36 (86%)
 Mutations within coding exons10 (9%)6 (14%)
Prioritized interphase FISH-25a
 17p deletion7 (6%)4 (10%)
 11q deletion5 (4%)5 (12%)
 Trisomy 1215 (13%)6 (14%)
 Normal karyotype29 (25%)9 (21%)
 13q deletion (sole abnormality)52 (46%)17 (40%)
 Ig Translocation2 (2%)0 (0%)
 FISH Data not available4 (4%)1 (2%)
IgVH Mutational status
 Unmutated (≥98% homology to germline)40 (35%)25 (60%)
 Mutated (<98% homology to germline)68 (60%)16 (38%)
 Not evaluable6 (5%)1 (2%)
ZAP-70 Expression
 Positive (>20%)35 (31%)30 (71%)
 Negative (≤20%)77 (68%)11 (26%)
 ZAP-70 Data not available2 (2%)1 (2%)
Treatment status at enrollment
 Not treated105 (92%)29 (69%)
 Treated9 (8%)13 (31%)
Number of prior therapies
 0105 (92%)29 (69%)
 17 (6%)9 (21%)
 22 (2%)2 (5%)
 >20 (0%)2 (5%)

Abbreviation: Ig, immunoglobulin.

  • aFISH findings in 25% of nuclei or more. Order of prioritization: 17p > 11q > trisomy 12 > 13q > Ig translocations > normal FISH.